UNASSIGNED: Encouragingly, asthma in most cases responds to treatment, including the use of an increasing number of biologic drugs in moderate to severe disease. This includes monoclonal antibody inhibitors of immunoglobulin E and cytokines, including interleukin 4, 5, or 13 and thymic stromal lymphopoietin. These limit mast cell and eosinophil activity that cause the symptomatic small airways obstruction and exacerbations.
UNASSIGNED: Despite humanization of the antibodies, it is evident that benralizumab; dupilumab; mepolizumab; omalizumab; reslizumab and tezepelumab all induce anti-drug antibodies to some extent. These can contribute to adverse events including infusion reactions, serum sickness, anaphylaxis and potentially disease activity due to loss of therapeutic function. Monitoring anti-drug antibodies (ADA) may allow prediction of future treatment-failure in some individuals allowing treatment cessation and switching therefore potentially limiting disease breakthrough.
■令人鼓舞的是,哮喘在大多数情况下对治疗有反应,包括在中度至重度疾病中使用越来越多的生物药物。这包括免疫球蛋白E和细胞因子的单克隆抗体抑制剂,包括白细胞介素4、5或13和胸腺基质淋巴细胞生成素。这些限制了肥大细胞和嗜酸性粒细胞的活动,导致有症状的小气道阻塞和恶化。
■尽管抗体人源化,很明显,贝那利珠单抗;dupilumab;美泊利单抗;奥马珠单抗;瑞利珠单抗和替齐单抗均在一定程度上诱导抗药物抗体.这些可能导致不良事件,包括输液反应,血清病,过敏反应和潜在的疾病活动由于丧失治疗功能。监测抗药物抗体(ADA)可以允许预测某些个体的未来治疗失败,从而允许治疗停止和转换,因此潜在地限制疾病突破。